AROA and Mölnlycke Partner to Expand U.S. Access to Endoform™
Image File
Original HTML

Exclusive co-promotion agreement combines AROA's regenerative tissue technology with Mölnlycke's wound care expertise and commercial reach

AUCKLAND, New Zealand, Oct. 20, 2026 /PRNewswire/ -- Aroa Biosurgery Limited (ASX: ARX), a soft tissue regeneration company, has entered into an exclusive agreement with Mölnlycke Healthcare US to co-promote Endoform™ in U.S. post-acute settings, effective October 16, 2026.

The agreement combines Endoform and AROA's proprietary AROA ECM™ technology with Mölnlycke's established wound care expertise and commercial reach. It is intended to bring Endoform to more clinicians and patients and support the product's continued growth.

AROA retains ownership of Endoform and AROA ECM technology and will continue to manufacture, distribute and supply the product. The arrangement also allows AROA to focus its resources on growing Myriad™ adoption in surgical settings and pursuing the opportunity for Symphony™ in outpatient wound care.

"We welcome the opportunity to partner with Mölnlycke, a well-established advanced wound care business known for excellence," said Brian Ward, AROA Founder and CEO. "Mölnlycke's deep expertise in wound care and broad commercial footprint provide a strong platform to bring Endoform to more clinicians and patients.

"This arrangement also allows us to concentrate our efforts on AROA's strategic priorities — sustaining Myriad's growth and pursuing the significant opportunity for Symphony, while continuing to manufacture and supply Endoform."

"Improving wound care requires strong partnerships and continued innovation," said Craig Kennedy, Mölnlycke VP Americas. "Our collaboration with AROA reflects a shared commitment to advancing clinical practice, supporting healthcare professionals, and improving patient outcomes. By adding Endoform to our advanced wound dressing portfolio, we're expanding the solutions available to clinicians and addressing the diverse needs of the patients they serve."

The agreement relates solely to Endoform in U.S. post-acute settings. AROA's other product portfolios and commercial arrangements, including Endoform distribution outside the United States, remain unchanged.

AROA's FY27 financial guidance remains unchanged at NZ$115–125 million in total revenue and NZ$8–11 million in normalized EBITDA.*

About Endoform

Endoform products are extracellular matrix products composed of AROA ECM, for the management of acute and chronic wounds in outpatient or post-acute settings.

About AROA Biosurgery

Aroa Biosurgery Limited (ASX: ARX) is a New Zealand-based soft tissue regeneration company developing and commercializing products for complex wounds and soft tissue reconstruction. Its products incorporate proprietary AROA ECM technology. For more information, visit www.aroa.com.

About Mölnlycke

Mölnlycke Health Care is a world-leading MedTech company specializing in innovative solutions for wound care and surgical procedures. Mölnlycke products and solutions are used daily by hospitals, health care providers and patients in over 100 countries around the world. Founded in 1849, Mölnlycke is owned by Patricia Industries, part of Investor AB, and is headquartered in Sweden. www.molnlycke.com.

SOURCE Aroa Biosurgery

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Need Review
Dedupe hash
prn_302914754
Press Eligible
Yes
Press Eligible Reason
Manuelle Prüfung nötig. Risiko: HIGH. Flags: ['finance', 'numbers']. Stichprobe: False
Source Name
Unknown Company
Original Summary

<p>Exclusive co-promotion agreement combines AROA's regenerative tissue technology with Mölnlycke's wound care expertise and commercial reach AUCKLAND, New Zealand, Oct. 20, 2026 /PRNewswire/ -- Aroa Biosurgery Limited (ASX: ARX), a soft tissue regeneration company, has entered into an...</p>

Original Link
Original Source
Image URL
https://mmx.prnewswire.com/media/MS1982633/Aroa-Biosurgery-Logo.jpg?id=OA3028513&p=facebook
Generated Article_json
{"target_audience": "b2b", "is_medical": true, "ai_generated_title": "AROA Hands Endoform US Post-Acute Promotion to Mölnlycke", "body_html": "<p><strong>Auckland -- [CURRENT_DATE] --</strong> Aroa Biosurgery (ASX: ARX) has signed an exclusive agreement with Mölnlycke Healthcare US to co-promote its Endoform wound product in U.S. post-acute settings, effective October 16, 2026, while leaving its FY27 guidance of NZ$115–125 million in revenue unchanged.</p><h5>AROA keeps ownership and manufacturing of Endoform</h5><p>AROA retains ownership of Endoform and its proprietary AROA ECM technology. It will continue to manufacture, distribute and supply the product. Mölnlycke adds Endoform to its advanced wound dressing portfolio and contributes its wound care expertise and commercial reach.</p><p>Endoform products are extracellular matrix products made from AROA ECM, used to manage acute and chronic wounds in outpatient or post-acute settings.</p><h5>Deal frees AROA resources for Myriad and Symphony</h5><p>The arrangement lets AROA concentrate on growing Myriad adoption in surgical settings and on pursuing the opportunity for Symphony in outpatient wound care. AROA Founder and CEO Brian Ward said Mölnlycke's broad commercial footprint provides a strong platform to bring Endoform to more clinicians and patients.</p><p>Craig Kennedy, Mölnlycke VP Americas, said the addition expands the solutions available to clinicians and addresses the diverse needs of their patients.</p><h5>Guidance holds at NZ$8–11 million normalized EBITDA</h5><p>AROA's FY27 financial guidance remains at NZ$115–125 million in total revenue and NZ$8–11 million in normalized EBITDA. The source does not disclose financial terms of the co-promotion agreement.</p><p>The agreement covers only Endoform in U.S. post-acute settings. AROA's other product portfolios and commercial arrangements, including Endoform distribution outside the United States, remain unchanged.</p>", "meta_description": "Aroa Biosurgery signs an exclusive deal with Mölnlycke to co-promote Endoform in U.S. post-acute care from Oct. 16, 2026; FY27 guidance of NZ$115–125M holds.", "seo_keywords": "Aroa Biosurgery, Mölnlycke, Endoform, co-promotion agreement, wound care, post-acute care, AROA ECM, Myriad, Symphony, ASX ARX", "companies": ["Aroa Biosurgery", "Mölnlycke Healthcare"], "industries": ["Healthcare & Biotech"], "markets_regions": ["United States", "Australia & New Zealand"], "news_type": ["partnership", "commercial_agreement"], "products": ["Endoform"], "themes": ["commercial_partnerships", "market_expansion"], "events": [], "cta_text": "Read the full Aroa Biosurgery and Mölnlycke co-promotion announcement", "learn_more": "", "fact_check": {"accuracy_score": 100, "legal_risk": "low", "corrections_made": [], "recommendation": "publish"}}
Content Hash (SHA-256, erste 32 hex)
81b9e12082bd16adbdad0925d0ce10d3